Greenwich LifeSciences, Inc.
Business
Greenwich LifeSciences is a clinical-stage biopharmaceutical company developing GLSI-100, an immunotherapy combining the GP2 peptide and GM-CSF to prevent breast cancer recurrence in HER2/neu-positive patients. The company is conducting the Phase III Flamingo-01 trial, which is enrolling patients in the U.S. and expanding into Europe with plans for up to 150 global sites. GLSI-100 is administered as intradermal injections in years 2-4 following standard trastuzumab treatment. The company operates through an exclusive license from the Henry M. Jackson Foundation and relies entirely on third-party contract manufacturers for supply.
Summary from 10-K filed 2026-06-01
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | |
| Research and development | 17 | 15 | 8 | 6 | 4 | |
| General and administrative | 2 | 2 | 2 | 2 | 1 | |
| Total operating expenses | 19 | 18 | 9 | 8 | 5 | |
| Loss from operations | −19 | −18 | −9 | −8 | −5 | |
| Interest income | 89,700 | 223,008 | 436,063 | 215,017 | 27,367 | |
| Net loss | −19 | −17 | −9 | −8 | −5 | |
| Net loss per common share, basic | −1.43 | −1.34 | −0.69 | −0.61 | −0.35 | |
| Net loss per common share, diluted | −1.43 | −1.34 | −0.69 | −0.61 | — | |
| Weighted average common shares outstanding, basic | 14 | 13 | 13 | — | — | |
| Weighted average common shares outstanding, diluted | 14 | 13 | 13 | 13 | — |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2025 2025-09-30 | FY 2025 2025-06-30 | FY 2025 2025-03-31 | FY 2024 2024-12-31 |
|---|---|---|---|---|---|---|
| Cash | 6 | — | — | — | 4 | |
| Total current assets | 6 | — | — | — | 4 | |
| Acquired patents, net | — | — | — | — | 1,779 | |
| Total assets | 6 | — | — | — | 4 | |
| Accounts payable & accrued interest | 5 | — | — | — | 3 | |
| Deferred compensation | 673,819 | — | — | — | 306,281 | |
| Unreimbursed expenses | 276,496 | — | — | — | 75,916 | |
| Total current liabilities | 6 | — | — | — | 3 | |
| Total liabilities | 6 | 2 | 3 | 3 | 3 | |
| Common stock, $0.001 par value; 100,000,000 shares authorized; 14,298,446 and 13,152,729 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | 14,299 | — | — | — | 13,153 | |
| Additional paid-in capital | 87 | — | — | — | 69 | |
| Accumulated deficit | −87 | — | — | — | −68 | |
| Total stockholders equity | 353,217 | — | — | — | 908,626 | |
| Total liabilities and stockholders equity | 6 | 4 | 3 | 3 | 4 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Amortization | 1,779 | 3,612 | 3,612 | 3,612 | 3,612 | |
| Stock-based compensation | 7 | 7 | 2 | 2 | 660,582 | |
| Accounts payable | 2 | 3 | 35,472 | — | −526,732 | |
| Deferred compensation | 367,538 | 306,281 | — | — | — | |
| Unreimbursed expenses (accrued) | 200,580 | 37,827 | −3,971 | −122,267 | 104,960 | |
| Net cash used in operating activities | −10 | −7 | −6 | −6 | −4 | |
| Sale of common stock via ATM program, net of costs | 12 | 2 | — | — | — | |
| Net proceeds from exercise of remaining underwriter warrants | 145,000 | — | — | — | — | |
| Sale of common stock via Private Placement, net of costs | — | 2 | — | — | — | |
| Net cash provided by financing activities | 12 | 4 | — | −8 | 3 | |
| Net increase (decrease) in cash | 2 | −3 | −6 | −14 | −1 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Greenwich LifeSciences, Inc.'s CIK number?
Greenwich LifeSciences, Inc.'s SEC CIK number is 0001799788 (1799788). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Greenwich LifeSciences, Inc.'s SEC filings?
All of Greenwich LifeSciences, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.